Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7

Article  PubMed  Google Scholar 

Posner MR, Haddad RI, Wirth L et al (2004) Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol 31:778–785

Article  CAS  PubMed  Google Scholar 

Pignon JP, Le Maitre A, Maillard E, Bourhis J (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomized trials and 17,346 patients. Radiother Oncol 92:4–14

Article  PubMed  Google Scholar 

Adelstein DJ, Li Y, Adams GL, Wagner JH, Kish JA, Ensley JF et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92–98

Article  PubMed  Google Scholar 

Brizel DM, Esclamado R (2006) Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. J Clin Oncol 24(17):2612–2617

Article  PubMed  Google Scholar 

Marcu L, van Doorn T, Olver I (2003) Cisplatin and radiotherapy in the treatment of locally advanced head and neck cancer—a review of their cooperation. Acta Oncol 42(4):315–325

Article  CAS  PubMed  Google Scholar 

Espeli V, Zucca E, Ghielmini M et al (2012) Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer. Oral Oncol 48:266–271

Article  CAS  PubMed  Google Scholar 

Fayette J, Molin Y, Lavergne E et al (2015) Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma. Drug Des Devel Ther 9:6203–6210

Article  CAS  PubMed  PubMed Central  Google Scholar 

Geiger JL, Lazim AF, Walsh FJ et al (2014) Adjuvant chemoradiation therapy with high-dose versus weekly cisplatin for resected, locally advanced HPV/p16-positive and negative head and neck squamous cell carcinoma. Oral Oncol 50:311–318

Article  CAS  PubMed  Google Scholar 

Tsan DL, Lin CY, Kang CJ et al (2012) The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity. Radiat Oncol 7:215

Article  CAS  PubMed  PubMed Central  Google Scholar 

Noronha V (2017) Phase III randomized trial comparing weekly versus 3-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer. In: 2017 American Society of Clinical Oncology Annual Meeting; Chicago, USA

Geeta SN, Padmanabhan TK, Samuel J, Pavithran K, Kuriakose MA (2006) Comparison of acute toxicities of two chemotherapy schedules for head and neck cancers. J Cancer Res Ther 2:100–104

Article  CAS  PubMed  Google Scholar 

Rawat S, Srivastava H, Ahlawat P et al (2016) Weekly versus three-weekly cisplatin-based concurrent chemoradiotherapy as definitive treatment in head and neck cancer—where do we stand? Gulf J Oncolog 1:6–11

CAS  PubMed  Google Scholar 

Ho KF, Swindell R, Brammer CV (2008) Dose intensity comparison between weekly and 3-weekly cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: a retrospective comparison from New Cross Hospital, Wolverhampton. UK Acta Oncol 47:1513–1518

Article  CAS  PubMed  Google Scholar 

Guan J, Zhang Y, Li Q et al (2016) A meta-analysis of weekly cisplatin versus three-weekly cisplatin chemotherapy plus concurrent radiotherapy for advanced head and neck cancer. Oncotarget 7:70185–70193

Article  PubMed  PubMed Central  Google Scholar 

Szturz P, Wouters K, Kiyota N et al (2017) Weekly low-dose versus three-weekly high dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data. Oncologist 22:1056–1066

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oosting SF et al (2016) Oral Oncol 59:43–49

Article  CAS  PubMed  Google Scholar 

Rothschild SI, Helfenstein S, Riesterer O et al (2017) 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: a multicentre, retrospective analysis. Ann Oncol 28:33–40. https://doi.org/10.1093/annonc/mdx374.021

Article  Google Scholar 

Sahoo TK, Samanta DR, Senapati SN, Parida K (2017) A comparative study on weekly versus three-weekly cisplatin-based chemoradiation in locally advanced head and neck cancers. J Clin Diagn Res. https://doi.org/10.7860/JCDR/2017/24765.9293

Article  PubMed  PubMed Central  Google Scholar 

Mitra D, Choudhury K, Rashid MA (2011) Concurrent chemotherapy in advanced head and neck carcinoma—a prospective randomized trial. Bangladesh J Otorhinolaryngol 17(2):88–95

Article  Google Scholar 

Rades D, Seidl D, Janssen S et al (2016) Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m2 for definitive radiochemotherapy of locally advanced head-and-neck cancers. BMC Cancer 16:437

Article  PubMed  PubMed Central  Google Scholar 

Azony AE, Sarhan AM, Hamouda WE, et al. (2012) Treatment outcome of concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck. ZUMJ. 18(5).

Jacinto JCK, Co J, Mejia MB, Regala EE (2017) The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma: a systematic review and meta-analysis. Br J Radiol 90:20170442

Article  PubMed  PubMed Central  Google Scholar 

Nutting CM, Morden JP, Harrington KJ et al (2011) Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 12(2):127–136

Article  PubMed  PubMed Central  Google Scholar 

Francis DO, Weymuller EA Jr, Parvathaneni U, Merati AL, Yueh B (2010) Dysphagia, stricture, and pneumonia in head and neck cancer patients: does treatment modality matter? Ann Otol Rhinol Laryngol 119(6):391–397

Article  PubMed  Google Scholar 

Miller MC, Agrawal A (2009) Hypothyroidism in postradiation head and neck cancer patients: incidence, complications, and management. Curr Opin Otolaryngol Head Neck Surg 17(2):111–115

Article  PubMed  Google Scholar 

Rybak LP (2007) Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 15(5):364–369

Article  PubMed  Google Scholar 

Givens DJ, Karnell LH, Gupta AK et al (2009) Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 135(12):1209–1217

Article  PubMed  Google Scholar 

Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73(9):994–1007

Article  CAS  PubMed  Google Scholar 

Hanigan MH, Devarajan P (2003) Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther 1:47–61

PubMed  PubMed Central  Google Scholar 

Machtay M, Moughan J, Trotti A et al (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26(21):3582–3589

Article  CAS  PubMed  PubMed Central  Google Scholar 

Machtay M, Moughan J, Farach A et al (2012) Hypopharyngeal dose is associated with severe late toxicity in locally advanced head-and-neck cancer: an RTOG analysis. Int J Radiat Oncol Biol Phys 84(4):983–989

Article  PubMed  PubMed Central  Google Scholar 

James M et al (2016) Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer. J Otolaryngol Head Neck Surg. https://doi.org/10.1186/s40463-016-0175-x

Article  Google Scholar 

Kunieda F, Kiyota N, Tahara M et al (2014) Randomized phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and ne